

12-05-02

1654
#10



EXPRESS MAIL CERTIFICATE

Date 2/4/02 Label No. EV208554845-US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

D Beck [Signature]
Name (Print) Signature

Customer No.:



Docket No.: 1946/1D864US1

07278

PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

David GSCHNEIDNER et al.

Serial No.: 09/762,067

Confirmation No.: 7883

Filed: August 3, 2001

For: COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS

RECEIVED

DEC 10 2002

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a

copy of Form PTO-1449 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with.

A concise explanation of the relevance of the foreign language documents as required by 37 CFR 1.98 is attached.

This submission is filed before a first action on the merits has been mailed.

The present Supplemental Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and in the course of each search, will review for


relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge the above deposit account for any deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: December 4, 2002



Jay R. Lessler
Registration No. 41,151
Attorney for Applicant(s)

DARBY & DARBY
Post Office Box 5257
New York, NY 10150-5257
(212) 527-7700



09/762067

Attachments
of # 10

RECEIVED

DEC 10 2002

TECH CENTER 1600/2900
SHEET 1 OF 1
(REV. 7-80)

U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 1946/1D864US1 SERIAL NO: 09/762,067
APPLICANT: David GSCHNEIDNER et al. FILING DATE: August 3, 2001
CONFIRMATION NO: 7883

U.S. PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
-------------------------------	----------------------------	-------------	-------------	--------------	-----------------	--------------------

FOREIGN PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION YES NO</u>
	1. 48-37819	11/14/1973	JP	A01N	C07C	abstract
	2. 4446	11/02/1966	FR	A61K	C07C	abstract
	3. WO 99/29705	6/17/1999	PCT	C07H	15/00	

OTHER REFERENCES

(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)

*EXAMINER
INITIALS

4. Palagiano, F. et al.: "Synthesis, stability and anticonvulsant activity of two new GABA prodrugs," *PHARAMAZIC*, 52 (4): 272-276 (1997), XP-001084051.
5. Yalcin, I. et al.: "Synthesis and Microbiological Activity of Some Novel N-(2-Hydroxyl-5-Substitutedphenyl)Benzacetamides, Phenoxyacetamides and Thiophenoxyacetamides as the Possible Metabolites of Antimicrobial Active Benzoxazoles," *IL FARMACO*, 52 (11), 685-689 (1997).

EXAMINER: _____

DATE CONSIDERED: _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.